Article
Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation.
Thrombosis and haemostasis - 1 Mar 2005
Kreuz Wolfhart, Gill Joan C, Rothschild Chantal, Manco-Johnson Marilyn J, Lusher Jeanne M, Kellermann Elke, Gorina Eduard, Larson Peter J
Abstract excerpt
The safety and efficacy of a full-length sucrose-formulated recombinant factor VIII product (rFVIII-FS; Kogenate FS; Kogenate Bayer) was evaluated in previously untreated (PUPs) and minimally treated (MTP) patients with severe haemophilia A (FVIII <2%). Patients (37 PUPs; 24 MTPs) aged 0.1-25.7 months were treated with rFVIII-FS for a cumulative of 9,141 exposure days (EDs), median 114 EDs (range 4-478), on...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.